Cabotegravir/Rilpivirine

DRUG4 trials

Sponsors

MRC/UVRI and LSHTM Uganda Research Unit, Yale University, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Shanghai Public Health Clinical Center

Conditions

AIDS-related LymphomaHIV InfectionHIV-1-infectionHiv

Phase 2

Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

Active, not recruitingNCT06411223

Yale UniversityHiv

Start: 2024-08-01End: 2027-03-01Updated: 2026-02-03

Phase 3

Improving HIV-1 Control in Africa with Long Acting Antiretrovirals

Active, not recruitingNCT05546242

MRC/UVRI and LSHTM Uganda Research UnitHIV-1-infection

Start: 2022-12-08End: 2026-03-31Updated: 2024-09-27

Unknown Phase

PERsistance of Long-Acting inJEctable CAB+RPV in a Cohort of Virologically-suppressed PLWH: a Real-life Study

Not yet recruitingNCT07579546

Fondazione Policlinico Universitario Agostino Gemelli IRCCSHIV-1-infection

Start: 2026-06-01End: 2027-06-01Target: 200Updated: 2026-05-12

Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma

RecruitingNCT07727642

Shanghai Public Health Clinical CenterAIDS-related Lymphoma, HIV Infection

Start: 2026-05-26End: 2028-07-01Target: 60Updated: 2026-07-27

Related Papers

Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA).

2025-03-28